# Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

> **NCT04707768** · PHASE3 · COMPLETED · sponsor: **Akebia Therapeutics** · enrollment: 456 (actual)

## Conditions studied

- Anemia Associated With Chronic Kidney Disease (CKD)

## Interventions

- **DRUG:** Vadadustat
- **DRUG:** Mircera®

## Key facts

- **NCT ID:** NCT04707768
- **Lead sponsor:** Akebia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-18
- **Primary completion:** 2023-01-06
- **Final completion:** 2023-01-30
- **Target enrollment:** 456 (ACTUAL)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04707768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04707768, "Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04707768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*